Published in
Elsevier, Journal of The American Academy of Dermatology, 2(58), p. 224-231
DOI: 10.1016/j.jaad.2007.07.042
Links
Tools
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
,
Kristian Reich,
Frank O. Nestle,
Richard K. Scher,
Shu Li,
Stephen Xu,
Ming-Chun Hsu,
Cynthia Guzzo,
Griffiths CEM Reich K Nestle F Scher R Li S Xu S Hsu M Guzzo C. Rich P.
Full text: Unavailable
Abstract
BACKGROUND: Although nail psoriasis occurs frequently in patients with psoriatic skin lesions, effective treatments are limited. OBJECTIVE: Occurrence of nail psoriasis by type and incidence of nail clearance using the Nail Psoriasis Severity Index were evaluated. METHODS: This was a 50-week, phase III study in which 378 patients with moderate to severe psoriasis were randomized 4:1 to infliximab (5 mg/kg) or placebo at weeks 0, 2, 6, and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. RESULTS: Of the 373 evaluated patients, 305 (81.8%) had baseline nail psoriasis. The right thumbnail was most often the worst involved nail, and pitting and onycholysis were the most common lesions. Among patients with baseline nail psoriasis, 6.9%, 26.2%, and 44.7% in the infliximab group had nail disease clearance at weeks 10, 24, and 50, respectively, versus 5.1% in the placebo group at week 24 (P